Boston Scientific Corporation 8-K Report: Key Financial Insights for January 2025

Here are the key insights extracted from the provided section of the financial report:

1. Company Identification:

• Name: Boston Scientific Corporation
• CIK Number: 0000885725
• Address: 300 Boston Scientific Way, Marlborough, MA 01752-1234
• Phone Number: 508-683-4000

2. SEC Filing Information:

• Filing Type: 8-K
• Filing Date: January 16, 2025
• Entity Type: Publicly traded company (Common Stock)

3. Stock Information:

• Common Stock:
• • Par Value: $0.01 per share
  • Ticker Symbol: BSX
  • Exchange: NYSE
• Debt Instrument:
• • Title: 0.625% Senior Notes due 2027
  • Ticker Symbol: BSX27
  • Exchange: NYSE

4. Reporting Context:

• The reporting period is specifically for January 16, 2025, indicating that this filing may contain information relevant to events or obligations occurring on that date.

5. Stock Classifications:

• The report includes information about different classes of stock, specifically:
• • Common Stock
  • Senior Notes due 2027

6. Namespaces and Schema:

• The document is structured using XBRL (eXtensible Business Reporting Language) and references specific namespaces related to US GAAP and the SEC.

Insights:

• The filing appears to be a formal disclosure of Boston Scientific’s financial instruments, including its common stock and senior notes, indicating the company's ongoing obligations and capital structure.
• The mention of a 0.625% senior note due in 2027 suggests the company is engaged in long-term debt financing, which could impact its financial leverage and interest expense.
• The specificity of the report date indicates relevance to investors and stakeholders regarding current financial conditions or corporate actions as of January 16, 2025.